#Sweden #Stockholm #dermatology #Nevisense #SciBase

Enhancing Biopsy Decision Accuracy with Nevisense

In a recent study, SciBase Holding AB, a pioneer in skin disorder solutions, revealed that the addition of Nevisense (Electrical Impedance Spectroscopy, EIS) as a decision-support tool leads to significant improvements in clinical accuracy for dermatologists in both the United States and Germany. The findings, published in the SKIN journal, showcase how integrating this innovative technology can alter the decision-making landscape for dermatologists and affect patient care.

A Comparative Study

The study analyzed two separate research projects, one from the US and another from Germany, aimed at assessing the effect of Nevisense on the biopsy decisions made by dermatologists. With statistics illustrating improved accuracy, it was noted that dermatologists using Nevisense made more informed biopsy decisions in cases of suspected malignant melanomas (MMs). The article highlights that while American dermatologists exhibited a higher rate of accurate biopsy decisions for MMs, their German counterparts were more adept at avoiding unnecessary biopsies for benign, pigmented skin lesions.

Divergent Practices and Training

The article delves into possible explanations for the differing outcomes between the two nations. It suggests that contrasting practice patterns, varying levels of training, and liability concerns (particularly in the US) may contribute to the higher biopsy rates observed among American dermatologists. These insights shed light on the psychological and regulatory influences impacting clinical decisions.

Dr. Pia Renaudin, CEO of SciBase, emphasized these distinctions, stating, "Cultural differences significantly affect clinical practices. US dermatologists exhibit a heightened fear of missing a melanoma, resulting in more biopsies, while their German counterparts are generally more conservative in this regard. The addition of Nevisense ensures that practitioners make more accurate decisions for their patients."

Implications for Patient Care

The study underscores the importance of EIS not only as a complementary tool to traditional dermoscopy but also as a means of refining biopsy decision-making. The implementation of Nevisense can lead to fewer unnecessary procedures, thus reducing patient anxiety and healthcare costs while enhancing clinical outcomes. This advancement is crucial, especially in an era where efficient healthcare management is paramount.

As the dermatological community increasingly adopts augmented intelligence solutions, the expectation is that technologies like Nevisense will become standard components in routine dermatological practice. Not only do they offer enhanced accuracy, but these tools also aid in fostering trust between physicians and patients by providing a higher level of confidence in the diagnostic process.

The Future of Dermatological Practices

As SciBase continues to drive innovation in the dermatology sector, the company remains committed to minimizing patient suffering through early detection and intervention. Established on more than two decades of research from the Karolinska Institute, SciBase has positioned itself as a leader in leveraging technology for better patient outcomes.

With Nevisense in the spotlight, the future looks promising for both clinicians and patients as this groundbreaking tool continues to reshape the landscape of dermatological diagnostics and treatment.

For further information about the study and its implications, you can access the article in SKIN journal. Read the full article here!.

About SciBase

SciBase is a global medical technology firm specializing in dermatological detection and prevention. Their pioneering work includes the development and commercialization of Nevisense, integrating cutting-edge AI technology and EIS to improve diagnostic accuracy.

SciBase proudly trades on the Nasdaq First North Growth Market and is dedicated to advancing healthcare through timely detection, ultimately aiming to save lives and reduce costs within the healthcare system.